Table 8.
Clinical characteristics of the surgical group that achieved ORR after treatment.
| Variables | Surgical group | Non-surgical group | P value |
|---|---|---|---|
| n=15 | n=38 | ||
| Sex (Female/Male) | 1 (6.7%)/14 (93.3) | 8 (21.1%)/30 (78.9%) | 0.395 |
| Age, year, median (Q1, Q3) | 48 (44, 57) | 54 (46,59.3) | 0.506 |
| Liver cirrhosis (No/Yes) | 4 (26.7%)/11 (73.3%) | 18 (47.4%)/20 (52.6%) | 0.285 |
| Child-Pugh (A/B) | 15 (100%)/0 (0%) | 37 (97.4%)/1 (2.6%) | 1.000 |
| ALBI, median (Q1, Q3) | -2.81 (-2.83, -2.57) | -2.76 (-2.90, -2.49) | 0.380 |
| ALBI grade (1/2) | 11 (73.3%)/4 (26.7%) | 25 (65.8%)/13 (34.2%) | 0.839 |
| HBsAg (Negative/Positive) | 2 (13.3%)/13 (86.7%) | 5 (13.2%)/33 (86.8%) | 1.000 |
| HBV-DNA load, IU/ml (≤2000/>2000) | 10 (66.7%)/5 (33.3%) | 23 (60.5%)/15 (39.5%) | 0.920 |
| Antivirus therapy (No/Yes) | 6 (40.0%)/9 (60.0%) | 23 (60.5%)/15 (39.5%) | 0.296 |
| AFP, μg/L (≤20/>20) | 5 (33.3%)/10 (66.7%) | 11 (28.9%)/27 (71.1%) | 1.000 |
| PIVKA-II, μg/L (≤37/>37) | 4 (26.7%)/11 (73.3%) | 7 (18.4%)/31 (81.6%) | 0.771 |
| CEA, μg/L (≤10/>10) | 14 (93.3%)/1 (6.7%) | 37 (97.4%)/1 (2.6%) | 1.000 |
| CA19-9, μg/L (≤39/>39) | 14 (93.3%)/1 (6.7%) | 27 (71.1%)/11 (28.9%) | 0.167 |
| Maximun tumor size, cm, median (Q1, Q3) | 5.0 (3.5, 12.6) | 6.2 (3.8, 9.7) | 0.837 |
| Tumor number (1/2/3/≥4) | 4 (26.7%)/7 (46.7%)/0 (0%)/4 (26.7%) | 19 (50.0%)/7 (18.4%)/3 (7.9%)/9 (23.7%) | 0.121 |
| Tumor number (Single/Multiple) | 4 (26.7%)/11 (73.3%) | 19 (50.0%)/19 (50.0%) | 0.216 |
| Lymph node metastasis (No/Yes) | 12 (80.0%)/3 (20.0%) | 35 (92.1%)/3 (7.9%) | 0.440 |
| Extrahepatic metastasis (No/Yes) | 13 (86.7%)/2 (13.3%) | 31 (81.6%)/7 (18.4%) | 0.969 |
| Marcovascular invasion | |||
| No | 10 (66.7%) | 24 (63.2%) | 0.838 |
| Portal vein | 1 (6.7%) | 6 (15.8%) | |
| Hepatic vein | 3 (20.0%) | 6 (15.8%) | |
| Portal vein combined with hepatic vein | 1 (6.7%) | 2 (5.3%) | |
| Marcovascular invasion (No/Yes) | 10 (66.7%)/5 (33.3%) | 24 (63.2%)/14 (36.8%) | 1.000 |
| Duration time, month, median (Q1, Q3) | 7.0 (2.0, 10.0) | 11.0 (6.0, 14.5) | 0.069 |
| Combined with PD-1 (No/Yes) | 9 (60.0%)/6 (40.0%) | 17 (44.7%)/21 (55.3%) | 0.486 |
| Combined with radiotherapy (No/Yes) | 10 (66.7%)/5 (33.3%) | 20 (52.6%)/18 (47.4%) | 0.535 |
| Combined with TACE (No/Yes) | 2 (13.3%)/13 (86.7%) | 5 (13.2%)/33 (86.8%) | 1.000 |
| BCLC (A/B/C) | 0 (0%)/7 (46.7%)/8 (53.3%) | 8 (21.1%)/8 (21.1%)/22 (57.9%) | 0.058 |
| CNLC stage (Ia-Ib/IIa-IIb/IIIa-IIIb) | 2 (13.3%)/5 (33.3%)/8 (53.3%) | 9 (23.7%)/8 (21.1%)/21 (55.3%) | 0.542 |
HCC, hepatocellular carcinoma; Q1, first quartile; Q3, third quartile; AFP, alpha-fetoprotein; PIVKA-II, Protein Induced by Vitamin K Absence or Antagonist-II; CA19-9, carbohydrate antigen 19-9; CEA, carcino-embryonic antigen; HBsAg, hepatitis B surface antigen; HBV-DNA, hepatitis B virus deoxyribonucleic acid; BCLC, Barcelona Clinic Liver Cancer; CNLC, China liver cancer staging.